E

AACR23 – is the Florida sun shining on KRAS?

Initial learnings on KRAS presentations at AACR23

April 17, 2023
E

Finding achilles heels to tackle cancer head on

Exploring new approaches to targeting cancer

January 20, 2022
E

Immuno-Oncology Gems in the ESMO Poster Halls

There was a lot going on in lung, melanoma, renal and colorectal cancer in terms of immunotherapy in Madrid.

November 3, 2014
E

Update on PD1 checkpoint inhibition in lung cancer

Merck announced their Breakthrough therapy designation for Keytruda in lung cancer this morning. What did we learn from the updated data for checkpoint inhibitors in NSCLC at ESMO that was different from ASCO?

October 27, 2014
E

New therapies are emerging for the treatment of advanced stomach cancer

Checkpoint inhibitors are looking very promising in advanced gastric cancer

October 23, 2014
E

Breathing New Life into Bladder Cancer Treatment

At ESMO 2014, phase 1 clinical trial data in bladder cancer was presented for Pembrolizumab (Merck) and MPDL3280A (Roche/Genentech).

October 22, 2014
E

Potential of IDO as Immunotherapy Target

Genentech and NewLink announced a deal to license an IDO inhibitor. What's the impact of this on the IO pipeline?

October 20, 2014
E

ESMO Posters Highlight New Cancer Drugs in Development

Posters on new cancer drugs in development with novel targets were presented at ESMO 2014 Congress in Madrid.

October 15, 2014
E

New drug targets may change Colorectal Cancer Landscape

Advances in Metastatic Colorectal Cancer may come from new druggable targets according to ESMO 2014 CRC Symposium

October 13, 2014
E

ESMO 2014: Update on the ALK lung cancer market

How is the ALK+ lung cancer market developing now that there are multiple next generation competitors following on from Xalkori and Zykadia? Check out our analysis of the developing landscape...

October 9, 2014
E

Did Galeterone ARMOR2 Prostate Cancer Data Impress at ESMO 2014?

At ESMO 2014 Mary-Ellen Taplin, MD (Dana-Farber Cancer Institute) presented the results of the Tokai Pharmaceuticals ARMOR2 clinical trial of galeterone in men with advanced prostate cancer.

October 3, 2014
E

ESMO 2014 Cancer Congress Day 3 Live Blog

Day 3 of the live blog from the ESMO 2014 Cancer Congress in Madrid.

September 28, 2014
E

ESMO 2014 Live Blog Day 2 #ESMO14

Day 2 Live Blog with news and commentary on what's taking place at the ESMO Cancer Congress in Madrid

September 28, 2014
E

ESMO 2014 Cancer Congress Day 1 Live Blog

ESMO 2014 Cancer Congress data starts to roll out today - throughout the day we'll be updating the blog with initial impressions of data as it's presented.

September 27, 2014
E

ESMO 2014 Takes Off with Release of Oral Abstracts #ESMO14

Most of the abstracts for oral presentations at the forthcoming ESMO cancer congress in Madrid have just been released. This is a preview of some that caught my attention.

September 24, 2014
E

ESMO 2014 Scientific Symposia Preview

There are some interesting science symposia at #ESMO14 in both immunotherapy and targeted therapies. We review what the hot topics are here.

September 19, 2014
E

ESMO 2014 Poster Preview

A review of the key poster and poster discussion abstracts on immunotherapy and targeted therapies at ESMO 2014

September 18, 2014
E

ESMO 2014 Preview: Immuno-oncology

Update on what to watch out for in immunotherapy at ESMO 2014.

September 16, 2014
E

ESMO 2014 Preview on Breast Cancer

Preview of some important breast cancer trials being presented in Madrid at #ESMO14.

September 10, 2014
E

What’s hot in Melanoma at ESMO 2014 Cancer Congress? #ESMO14

With the recent FDA approval of Pembrolizumab (Keytruda) we can expect melanoma to be a hot topic at ESMO 2014.

September 5, 2014
E

What’s hot in prostate cancer at ESMO 2014? #ESMO14

Preview of Prostate Cancer oral presentations at ESMO 2014 Cancer Congress in Madrid.

September 2, 2014
E

ESMO 2014 Congress Plenary Preview #ESMO14

Review of the preliminary programme and late breakers in the Presidential Symposia at ESMO 2014.

August 28, 2014
E

ESMO 2014 Cancer Congress bans Press, Nurses and Patient Advocates from Exhibits and Symposia #ESMO14

Restricting the freedom of the press and creating a two-tier access to information at major medical meetings such as ESMO 2014 is both pernicious and toxic.

August 25, 2014
E

ESMO 2014 Madrid Congress Preview #ESMO14

2014 Congress of the European Society for Medical Oncology (ESMO) is set to take place this year in Madrid from September 26 to 30th.

August 22, 2014